Please login to the form below

Not currently logged in
Email:
Password:

Santarus begins Zegerid litigation against Par

US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.

US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.

The University of Missouri, which is licensor of the patents, has joined Santarus in the litigation as a co-plaintiff.

The lawsuit refers to an Abbreviated New Drug Application (ANDA) filed by Par with the FDA to market a generic version of Zegerid Capsules before the 2016 expiration of three listed US patents (6,645,988, 6,489,346 and 6,699,885).

Santarus filed the lawsuit within the 45 days limit required to prevent the FDA from approving París ANDA for 30 months, or until a district court decision ruling against Santarus.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics